Chicago biotech Emalex says it cleared a Phase 3 for Tourette syndrome, will seek FDA approval

Kyle LaHucik

Senior Reporter

Emalex Biosciences said its daily oral tablet helped reduce relapses for children and adults with Tourette syndrome in a Phase 3 study, and now plans …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Chicago biotech Emalex says it cleared a Phase 3 for Tourette syndrome, will seek FDA approval

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Where the money is: The top 100 venture investors in biotech

J&J seeks to stop Samsung Bioepis from licensing Stelara biosimilar

Lilly pays $10M upfront for Organovo’s FXR agonist program

Compounders sue FDA over removal of semaglutide from official shortage list

Candel's viral therapy shows promising survival in small pancreatic cancer study

How AI can address ongoing challenges in the life sciences industry

Chica­go biotech Emalex says it cleared a Phase 3 for Tourette syn­drome, will seek FDA ap­proval

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Where the mon­ey is: The top 100 ven­ture in­vestors in biotech

J&J seeks to stop Sam­sung Bioepis from li­cens­ing Ste­lara biosim­i­lar

Lil­ly pays $10M up­front for Organo­vo’s FXR ag­o­nist pro­gram

Com­pounders sue FDA over re­moval of semaglu­tide from of­fi­cial short­age list

Can­del's vi­ral ther­a­py shows promis­ing sur­vival in small pan­cre­at­ic can­cer study

How AI can ad­dress on­go­ing chal­lenges in the life sci­ences in­dus­try

Chicago biotech Emalex says it cleared a Phase 3 for Tourette syndrome, will seek FDA approval

Where the money is: The top 100 venture investors in biotech

J&J seeks to stop Samsung Bioepis from licensing Stelara biosimilar

Lilly pays $10M upfront for Organovo’s FXR agonist program

Compounders sue FDA over removal of semaglutide from official shortage list

Candel's viral therapy shows promising survival in small pancreatic cancer study

How AI can address ongoing challenges in the life sciences industry